JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
140.79
+0.41 (+0.29%)
As of 12:40PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close140.38
Open141.25
Bid140.87 x 800
Ask140.88 x 1400
Day's Range140.34 - 141.84
52 Week Range109.16 - 157.00
Volume2,284,748
Avg. Volume8,543,139
Market Cap371.172B
Beta (5Y Monthly)0.70
PE Ratio (TTM)21.97
EPS (TTM)6.41
Earnings DateJul. 16, 2020
Forward Dividend & Yield4.04 (2.87%)
Ex-Dividend DateMay 22, 2020
1y Target Est164.24
  • Will Legal Problems Bankrupt Johnson & Johnson?
    Motley Fool

    Will Legal Problems Bankrupt Johnson & Johnson?

    A flurry of legal challenges is always a good reason for investors to be wary of a company. Lawsuits related to its talc-based products and the company's role in the opioid crisis present some of the biggest risks to long-term investors. Although J&J may be able to manage those legal challenges today, that doesn't mean it always will.

  • Better Buy: Eli Lilly vs. Johnson & Johnson
    Motley Fool

    Better Buy: Eli Lilly vs. Johnson & Johnson

    As two of the largest healthcare companies in the world, both Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) have a role to play in well-balanced healthcare portfolios. With a profit margin of 23.8%, 15.1% year-over-year quarterly revenue growth, and trailing-12-month revenues of $23.1 billion, Eli Lilly exudes success.

  • This Under-the-Radar Stock Is a Better Way to Bet on Coronavirus Vaccines
    Motley Fool

    This Under-the-Radar Stock Is a Better Way to Bet on Coronavirus Vaccines

    Emergent BioSolutions has become the go-to manufacturing partner for companies looking to develop vaccines for the coronavirus.

  • J&J (JNJ) Discontinues Phase III Study of Stelara for Lupus
    Zacks

    J&J (JNJ) Discontinues Phase III Study of Stelara for Lupus

    Johnson & Johnson (JNJ) discontinues phase III study of Stelara (ustekinumab) in systemic lupus erythematosus.

  • Bayer Isn’t Out of the Roundup Woods as 30,000 Claims Remain
    Bloomberg

    Bayer Isn’t Out of the Roundup Woods as 30,000 Claims Remain

    (Bloomberg) -- While Bayer AG said it took a major step toward wrapping up litigation over its Roundup weedkiller with a settlement of almost $11 billion, the company still faces about 30,000 unresolved cancer claims that could cost billions, and lawyers are vowing even more lawsuits.“If Bayer and its investors thought the Roundup litigation was wrapped up in a nice, neat ball with this settlement, they are sadly mistaken,” said Tom Kline, a Philadelphia-based plaintiffs’ lawyer who won an $8 billion verdict against Johnson & Johnson last year over one of its anti-psychotic drugs. “We are working hard getting these cases in and ready for trial.”Roundup litigation was by far the biggest liability that the German chemical giant inherited when it acquired Monsanto for $63 billion in 2018. On Wednesday, Bayer announced settlements totaling $12.1 billion that included as much as $10.9 billion for Roundup, $820 million for toxic-chemical pollution and $400 million related to damage from a dicamba-based herbicide.But Bayer only managed agreements to end about 95,000 of the 125,000 lawsuits claiming Roundup caused cancer. The others refused to settle, and the number of cases is growing. Last week, attorney Fletch Trammell filed 13 suits on behalf of kids who developed non-Hodgkin’s lymphoma after being exposed to the weedkiller in backyards, parks and playgrounds.Read More: How Roundup Went From Bayer Asset to Burden“The settlement announcement feels like Bayer is trying to stop a gigantic problem by putting its finger in the proverbial dam,” said Jason Itkin, a Houston based lawyer who won a $70 million verdict against J&J last year. “Every day, new people are diagnosed with Roundup-induced cancer. There will be thousands and thousands of future cases because Bayer is currently still selling this dangerous product.”The company denies Roundup’s active ingredient, glyphosate, is a carcinogen, a position backed by the U.S. Environmental Protection Agency.William Dodero, Bayer’s global head of litigation, said at a press conference Wednesday he couldn’t predict how many new Roundup cases will emerge. But the Leverkusen, Germany-based company has made progress in ending its Roundup litigation, resolving all the cases set for trial and those brought by the plaintiffs’ lawyers leading the litigation, Dodero said.The settlements must still be approved by a federal judge in San Francisco who has some of the cases consolidated before him.“This litigation has been going on for four years with speculation about settlement for more than a year and plaintiff attorneys have had ample opportunity to bring forward claims,” Chris Loder, a company spokesman, said in an emailed statement. “We’ve now settled approximately 75% of claims, resolved cases with all leaders” on the plaintiffs side and “have an allowance to resolve the remaining cases.”Shareholders seemed to welcome the agreements. Bayer’s American depositary receipts climbed on the settlement news, gaining as much as as 5%. The ADRs, which represent one-quarter of a regular share, were up 15 cents to $20.54 at 5:19 p.m. in New York.The company made offers to all the holdouts and is “confident that we can bring this to a final closure in due course,” Dodero said.Too LowBut Bayer’s settlement offers were insultingly low, according to James Onder, a St. Louis lawyer who held his 24,000 cases out of the settlement.“The unsettled legal exposure for Bayer could easily exceed tens of billions of dollars as our firms and others have rejected the minuscule offers accepted by some other lawyers,” Onder said in an email. “To act as if one quarter of the Roundup cancer victims don’t exist is nothing more than a flagrant attempt by Bayer to manipulate its stock price and serves as a slap in the face” to those victims, he said.After Bayer officials refused to make “serious” settlement offers, Trammell said he filed the 13 state court cases on behalf of families who say their children developed non-Hodgkin’s lymphoma from Roundup exposure. Eleven suits were filed in St. Louis last week and the others were file in San Francisco, he said.The children range in age from five to 17, according to court filings. Most are still battling their cancers, but 13-year-old Jacob Savage of Forks, Washington, died in 2017. Bayer has been hit with at least 20 other suits involving children and Roundup, court dockets show.“I’m happy they didn’t settle with me and that I can go out and get more good cases,” said Mark Robinson, a California attorney. “These guys need a couple of more verdicts against them to start valuing the cases properly.”The company lost three damage verdicts totaling more than $191 million. While those cases are on appeal, they spurred a surge in new filings over the past year that led to a plunge in Bayer shares.Precautions taken by courts during the Covid-19 pandemic -- including suspensions of jury selection -- may make it difficult for any of the plaintiff laywers to get cases set for trial until at least next year, said Ken Feinberg, who is serving as the chief settlement mediator in the Roundup cases.“I predict all the remaining cases will settle within a few months,” Feinberg said. “People are going to want their share of this settlement.”Glenn Norton, a retired Missouri appellate judge who served as a mediator for cases in St. Louis and worked with Feinberg on national settlements, said lawyers whose cases weren’t part of Wednesday’s agreement are still “determined to get them settled, too.”Norton said “Bayer paid a little more than people thought they would” to resolve most of the Roundup cases, which shows company officials were keen to get as much of the litigation behind them as possible.The consolidated case is In re: Roundup Products Liability Litigation, MDL 2741, U.S. District Court, Northern District of California (San Francisco).(Updates comment from mediator Norton. An earlier version of this story corrected a comment by the chief mediator, Feinberg.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Vaccine makers face biggest medical manufacturing challenge in history
    Reuters

    Vaccine makers face biggest medical manufacturing challenge in history

    From deploying experts amid global travel restrictions to managing extreme storage conditions, and even inventing new kinds of vials and syringes for billions of doses, the path is strewn with formidable hurdles, according to Reuters interviews with more than a dozen vaccine developers and their backers. Any hitch in an untested supply chain - which could stretch from Pune in India to England's Oxford and Baltimore in the United States - could torpedo or delay the complex process. Col. Nelson Michael, director of the U.S. Army's Center for Infectious Disease Research who is working on the government's "Warp Speed" project to deliver a vaccine at scale by January, said companies usually have years to figure this stuff out.

  • Reuters

    INSIGHT-Vaccine makers face biggest medical manufacturing challenge in history

    From deploying experts amid global travel restrictions to managing extreme storage conditions, and even inventing new kinds of vials and syringes for billions of doses, the path is strewn with formidable hurdles, according to Reuters interviews with more than a dozen vaccine developers and their backers. Any hitch in an untested supply chain - which could stretch from Pune in India to England's Oxford and Baltimore in the United States - could torpedo or delay the complex process. Col. Nelson Michael, director of the U.S. Army's Center for Infectious Disease Research who is working on the government's "Warp Speed" project to deliver a vaccine at scale by January, said companies usually have years to figure this stuff out.

  • Reuters

    Unilever, rivals mull changes amid global backlash against skin-lightening products

    Unilever is considering marketing changes to its dominant line of skin lightening creams, according to a company source in South Asia, even as the company and its rivals face a growing global social media backlash against such products. Products marketed as skin lightening have a huge market in South Asia, due to a societal obsession with fairer skin tones. Unilever's 'Fair & Lovely' brand dominates the market in South Asia, while similar products are sold by L'Oréal and Procter & Gamble.

  • Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict
    Zacks

    Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict

    J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.

  • Reuters

    PRESS DIGEST- New York Times business news - June 24

    - TaskRabbit chief executive Stacy Brown-Philpot, one of the few prominent black women in Silicon Valley, is stepping down after four years running the San Francisco-based marketplace for gig workers. - A Missouri appeals court on Tuesday ordered Johnson & Johnsonc and a subsidiary to pay $2.1 billion in damages to women who blamed their ovarian cancers on the company's talcum products, including its iconic baby powder.

  • PRESS DIGEST - Wall Street Journal - June 24
    Reuters

    PRESS DIGEST - Wall Street Journal - June 24

    June 24 (Reuters) - The following are the top stories in the Wall Street Journal on Wednesday.

  • How the NACP ETF helps investors align their assets with their values
    Yahoo Finance Video

    How the NACP ETF helps investors align their assets with their values

    Ethan Powell, CEO of Impact Shares, joined The Final Round to discuss socially responsible investing and the Impact Shares NAACP Minority Empowerment ETF.

  • J&J loses bid to overturn baby powder verdict, but damages cut to $2.12 billion
    Reuters

    J&J loses bid to overturn baby powder verdict, but damages cut to $2.12 billion

    The Missouri Court of Appeals lowered the original $4.69 billion verdict from July 2018 after dismissing claims by some of the 22 women and their families who had sued. "Plaintiffs proved with convincing clarity that defendants engaged in outrageous conduct because of an evil motive or reckless indifference," the court said.

  • Reuters

    Damages verdict against Johnson & Johnson lowered to $2.1 bln in Missouri talc case

    A Missouri appeals court on Tuesday reduced a damages award against Johnson & Johnson to about $2.12 billion from $4.69 billion in a case brought by 22 women who blamed their ovarian cancer on asbestos in its baby powder and other talc products. Johnson & Johnson had been appealing a July 2018 jury verdict.

  • Reuters

    Johnson & Johnson drops skin whitening creams

    Johnson & has decided to stop selling skin whitening creams popular in Asia and the Middle East, it has said, after such products have come under renewed social pressure in recent weeks amid a global debate about racial inequality. Johnson & Johnson will stop selling its Clean & Clear Fairness line of products, sold in India, a spokeswoman told Reuters on Friday. News that it would pull its Neutrogena Fine Fairness line, available in Asia and the Middle East, was reported earlier this month.

  • Coronavirus update: New case spikes whipsaw market; Fauci warns US may not be ready for football
    Yahoo Finance

    Coronavirus update: New case spikes whipsaw market; Fauci warns US may not be ready for football

    A resurgence of coronavirus cases in key U.S. regions is nudging nationwide numbers higher, casting doubt on state efforts to relax lockdowns.

  • Johnson & Johnson in talks with governments on possible COVID-19 vaccine
    Reuters

    Johnson & Johnson in talks with governments on possible COVID-19 vaccine

    Johnson & Johnson is in talks with multiple governments and global organisations as it seeks to develop a COVID-19 vaccine, it said on Thursday after Reuters reported that the U.S. company is in talks over a potential EU supply deal. "We are committed to making our COVID-19 vaccine accessible globally to populations at greatest risk and where it could provide the greatest good according to our vaccine's profile," a Johnson & Johnson spokesman said in an email. "As part of that, we are in ongoing discussions with many stakeholders, including national governments and global organisations."

  • Exclusive: EU in advanced talks with Johnson & Johnson on COVID-19 vaccine deal - sources
    Reuters

    Exclusive: EU in advanced talks with Johnson & Johnson on COVID-19 vaccine deal - sources

    The European Commission is in advanced talks with pharmaceuticals giant Johnson & Johnson <JNJ.N> to reserve or make an up-front purchase of its COVID-19 vaccine under development, two officials familiar with the talks told Reuters. The move would be the first arranged by the European Union executive since it was mandated by the 27 EU national governments to use an emergency fund of more than 2 billion euros (£1.8 billion) to strike deals with up to six vaccine producers. The Commission's deal with U.S. company Johnson & Johnson is "in the pipeline", a top health official from an EU member state said, asking to remain anonymous because because the talks were confidential discussions about vaccines between the EU executive and EU governments.

  • Coronavirus update: States struggle to balance reopening with creeping rise in cases
    Yahoo Finance

    Coronavirus update: States struggle to balance reopening with creeping rise in cases

    The pandemic is heaping pressure on the drug industry to meet lofty expectations surrounding effective treatments.

  • The Zacks Analyst Blog Highlights: JNJ, WMT, BAC, IBM and LMT
    Zacks

    The Zacks Analyst Blog Highlights: JNJ, WMT, BAC, IBM and LMT

    The Zacks Analyst Blog Highlights: JNJ, WMT, BAC, IBM and LMT

  • U.S. narrows list of promising COVID-19 vaccine candidates to about 7
    Reuters

    U.S. narrows list of promising COVID-19 vaccine candidates to about 7

    U.S. President Donald Trump's administration is narrowing its list of promising experimental coronavirus vaccines to about seven from 14, the U.S. Department of Health and Human Services said on Tuesday. The announcement is part of the administration's "Operation Warp Speed", the White House program to accelerate coronavirus vaccine development. The New York Times reported earlier this month that the White House had selected five companies, including Moderna Inc , AstraZeneca Plc and Pfizer Inc, as the most likely candidates to produce a vaccine for the novel coronavirus.

  • Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
    Zacks

    Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $141.25, moving -0.63% from the previous trading session.

  • Top Research Reports for Johnson & Johnson, Walmart & Bank of America
    Zacks

    Top Research Reports for Johnson & Johnson, Walmart & Bank of America

    Top Research Reports for Johnson & Johnson, Walmart & Bank of America